Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01634620 · ClinicalTrials.gov registry record
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
A clinical trial, sponsored by Aerocrine AB.
- Completed
- Registry status
- 200
- Enrollment target
NCT01634620: Completed study, sponsored by Aerocrine AB.
NCT01634620 is a clinical trial that has completed, run by Aerocrine AB. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01634620 has completed, sponsored by Aerocrine AB.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference product: NIOX MINO® Instrument (09-1100) Performance assessments: Fractional Exhaled Nitric Oxide (FeNO) Measurements will be performed according to the "Perform FeNO Measurement" guidelines on page 7 of the NIOX MINO® User Manual Safety assessments: The Investigator is responsible for the detection, reporting, and documentation of events meeting the definition of an Adverse Event (AE) and/or Serious Injuries as provided in this clinical investigation plan from the time that informed consent has been provided and during the study period Criteria for evaluations: This is an observational, pilot study and there are currently no plans for a formal statistical analysis. Information gained from this study may used to design subsequent studies in patients with chronic obstructive airways disease. Information collected will be summarized in a clinical study report but will not be subject to formal hypothesis testing
Interventions
- DEVICE NIOX MINO® Instrument (09-1100)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01634620
The ClinicalTrials.gov registry entry for NCT01634620 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerocrine AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NIOX MINO® Instrument (09-1100) is the first listed.
NCT01634620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01634620 about?
NCT01634620 is a clinical study titled "Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease". Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference product: NIOX MINO® Instrument (09-1100) Performance assessments: Fr...
What is the current status of trial NCT01634620?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2012-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01634620?
The interventions under investigation include: NIOX MINO® Instrument (09-1100) (DEVICE).
Who is sponsoring clinical trial NCT01634620?
This trial is sponsored by Aerocrine AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.